Complete reference list (PDF 1191 KB) - Department of Health and ...
Complete reference list (PDF 1191 KB) - Department of Health and ...
Complete reference list (PDF 1191 KB) - Department of Health and ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
69. Joura EA, Leodolter S, Hern<strong>and</strong>ez-Avila M, et al. Efficacy <strong>of</strong> a quadrivalent prophylactic human<br />
papillomavirus (types 6, 11, 16, <strong>and</strong> 18) L1 virus-like-particle vaccine against high-grade vulval<br />
<strong>and</strong> vaginal lesions: a combined analysis <strong>of</strong> three r<strong>and</strong>omised clinical trials. The Lancet<br />
2007;369:1693-702.<br />
70. Paavonen J, Naud P, Salmerón J, et al. Efficacy <strong>of</strong> human papillomavirus (HPV)-16/18 AS04-<br />
adjuvanted vaccine against cervical infection <strong>and</strong> precancer caused by oncogenic HPV types<br />
(PATRICIA): final analysis <strong>of</strong> a double-blind, r<strong>and</strong>omised study in young women. [erratum<br />
appears in Lancet. 2010 Sep 25;376(9746):1054]. The Lancet 2009;374:301-14.<br />
71. GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy <strong>and</strong> immunogenicity <strong>of</strong> the<br />
human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis <strong>of</strong> a r<strong>and</strong>omised placebocontrolled<br />
trial up to 6.4 years. The Lancet 2009;374:1975-85.<br />
72. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade<br />
cervical lesions. New Engl<strong>and</strong> Journal <strong>of</strong> Medicine 2007;356:1915-27.<br />
73. Hildesheim A, Herrero R, Wacholder S, et al. Effect <strong>of</strong> human papillomavirus 16/18 L1 viruslike<br />
particle vaccine among young women with preexisting infection: a r<strong>and</strong>omized trial. JAMA<br />
2007;298:743-53.<br />
74. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy <strong>of</strong> quadrivalent HPV vaccine against HPV<br />
Infection <strong>and</strong> disease in males. [erratum appears in N Engl J Med. 2011 Apr 14;364(15):1481].<br />
New Engl<strong>and</strong> Journal <strong>of</strong> Medicine 2011;364:401-11.<br />
75. Petäjä T, Keränen H, Karppa T, et al. Immunogenicity <strong>and</strong> safety <strong>of</strong> human papillomavirus<br />
(HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10–18 years. Journal <strong>of</strong> Adolescent<br />
<strong>Health</strong> 2009;44:33-40.<br />
76. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact <strong>of</strong> quadrivalent human papillomavirus<br />
(HPV; types 6, 11, 16, <strong>and</strong> 18) L1 virus-like particle vaccine on infection <strong>and</strong> disease due to<br />
oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. Journal <strong>of</strong><br />
Infectious Diseases 2009;199:926-35.<br />
77. Wheeler CM, Castellsagué X, Garl<strong>and</strong> SM, et al. Cross-protective efficacy <strong>of</strong> HPV-16/18 AS04-<br />
adjuvanted vaccine against cervical infection <strong>and</strong> precancer caused by non-vaccine oncogenic<br />
HPV types: 4-year end-<strong>of</strong>-study analysis <strong>of</strong> the r<strong>and</strong>omised, double-blind PATRICIA trial.<br />
[erratum appears in Lancet Oncol. 2012 Jan;13(1):e1]. The Lancet Oncology 2012;13:100-10.<br />
78. Bonanni P, Cohet C, Kjaer SK, et al. A summary <strong>of</strong> the post-licensure surveillance initiatives for<br />
GARDASIL/SILGARD ® . Vaccine 2010;28:4719-30.<br />
79. De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy <strong>and</strong> immunogenicity <strong>of</strong><br />
the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine<br />
2010;28:6247-55.<br />
80. Harper DM, Vierthaler SL. Next generation cancer protection: the bivalent HPV vaccine for<br />
females. ISRN Obstetrics <strong>and</strong> Gynecology 2011;2011:457204. doi:10.5402/2011/457204.<br />
81. Neuzil KM, Canh do G, Thiem VD, et al. Immunogenicity <strong>and</strong> reactogenicity <strong>of</strong> alternative<br />
schedules <strong>of</strong> HPV vaccine in Vietnam: a cluster r<strong>and</strong>omized noninferiority trial. JAMA<br />
2011;305:1424-31.<br />
82. Esposito S, Birlutiu V, Jarcuska P, et al. Immunogenicity <strong>and</strong> safety <strong>of</strong> human papillomavirus-<br />
16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule<br />
compared with the st<strong>and</strong>ard dosing schedule in healthy women aged 15 to 25 years: results from a<br />
r<strong>and</strong>omized study. Pediatric Infectious Disease Journal 2011;30:e49-55.<br />
83. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Pro<strong>of</strong>-<strong>of</strong>-principle evaluation <strong>of</strong> the efficacy <strong>of</strong><br />
fewer than three doses <strong>of</strong> a bivalent HPV16/18 vaccine. Journal <strong>of</strong> the National Cancer Institute<br />
2011;103:1444-51.<br />
84. Krajden M, Cook D, Yu A, et al. Human papillomavirus 16 (HPV 16) <strong>and</strong> HPV 18 antibody<br />
responses measured by pseudovirus neutralization <strong>and</strong> competitive Luminex assays in a twoversus<br />
three-dose HPV vaccine trial. Clinical <strong>and</strong> Vaccine Immunology: CVI 2011;18:418-23.<br />
85. National vaccine storage guidelines: Strive for 5. Canberra: Australian Government <strong>Department</strong> <strong>of</strong><br />
<strong>Health</strong> <strong>and</strong> Ageing, 2005. Available at:<br />
http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/provider-store<br />
(accessed July 2011).<br />
86. Reisinger KS, Block SL, Collins-Ogle M, et al. Safety, tolerability, <strong>and</strong> immunogenicity <strong>of</strong><br />
Gardasil given concomitantly with Menactra <strong>and</strong> Adacel. Pediatrics 2010;125:1142-51.
Change language